Journals | Policy | Permission

Journal of Clinical Medicine Research

Case Report

Volume 8, Number 4, April 2016, pages 334-337

Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet’s Disease: Eight Consecutive Cases

Behcet’s disease (BD) is a chronic inflammatory disease characterized by repeated periods of remission and deterioration of oral and genital ulcers, along with ocular or skin involvements [1]. These manifestations are caused by systemic vasculitis. Intestinal BD, which is associated with symptoms of abdominal pain and diarrhea, is a specific subtype of BD that accounts for approximately 3-16% of BD cases [2].

Conventionally pharmacological treatments include 5-aminosalicylic acid (5-ASA), systemic corticosteroids, and immunosuppressive agents such as thiopurines [3-5]. However, many patients fail to respond to these treatments [6, 7]. The clinical outcomes for these agents in the treatment of intestinal BD are thus limited. In recent years, accumulating evidence on the efficacy of infliximab (IFX), an anti-tumor necrosis factor (TNF)-α agent, in the management of Behcet’s uveitis [8], has encouraged the use of anti-TNF-α agents for management of intestinal BD [9]. Very recently, adalimumab (ADA) has been demonstrated to be effective and safe for patients with intestinal BD [10]. As a consequence, ADA was approved for intestinal BD in Japan in 2013. However, in the clinical setting, little information is currently available regarding the long-term efficacy of ADA against intestinal BD [11].

This study retrospectively assessed the 52-week efficacy of ADA for intestinal BD refractory to conventional treatments including 5-ASA, corticosteroids, and thiopurines.

Between October 2010 and July 2015, eight consecutive patients were referred to Nagoya City University Hospital for the treatment of intestinal BD. Patients were diagnosed with BD according to diagnostic criteria defined by the BD Research Committee of Japan [12]. Briefly, BD that includes four major features (recurrent oral ulceration, genital ulceration, ocular lesion, and typical skin lesion) is classified as complete-type BD, while BD with three major features, or two major and two minor features (arthritis without deformity and ankylosis, ileocecal ulcers, epididymitis, vascular lesions or central nervous system symptoms), or typical ocular lesion plus one major or two minor features is classified as incomplete-type BD, and BD with one major feature is classified as suspected BD.

The eight patients, including one with postoperative recurrence, were given ADA 160 mg in week 0, 80 mg in week 2, and 40 mg every other week over 52 weeks for refractory BD that failed to respond to conventional treatments including mesalazine (MLZ) or prednisolone (PSL), and azathioprine (AZA). Global gastrointestinal (GI) symptom score and endoscopic assessment were performed as previously reported [10]. The primary outcome was the percentage of patients showing marked improvement (MI) (score 0 or 1 for both global GI symptoms and endoscopic assessments) at 10 and 52 weeks after starting ADA, and secondary outcomes were the percentage of clinical remission (score 0 for both global GI symptoms and endoscopic assessments). Any adverse event was recorded, along with date of onset, severity, outcome, and relationship of event to these therapies. Data are presented as mean value. Missing data were imputed using last observation carried forward (LOCF) [10]. Data are presented as means ± standard error of the mean, and comparisons were made using a paired t-test. A significance level of 0.05 was used for all statistical tests, and two-tailed tests were applied when appropriate.

The demographic data are shown in Table 1. Mean age was 46.6 years. Disease type included seven incomplete cases and one suspected case. Ulcer size at the ileocecal valve included two cases with ulcers of 1 - 2 cm, three cases of 2 - 3 cm, and three cases of ≥ 3 cm. Concurrent medications included MLZ, PSL, and AZA. Of the eight patients receiving ADA (160/80/40 mg every other week), five patients (62.5%) achieved MI at 10 weeks, and six (75%) patients showed MI at 52 weeks. In addition, complete remission was obtained in two patients (25%) at both 10 and 52 weeks. Repeated oral aphtha persisted in three patients without other major features after starting ADA (Table 2). Improvement of global GI symptoms to a score of ≤ 1 was seen in six patients (75%) at 10 weeks and eight patients (100%) at 52 weeks. Furthermore, improvement to score 0 was seen in three patients (37.5%) at 10 weeks and four patients (50%) at 52 weeks, respectively (Fig. 1A). Moreover, improvement of endoscopic assessment to a score of ≤ 1 was also seen with seven patients (87.5%) at 10 weeks and six patients (75%) at 52 weeks, respectively. A score of 0 was seen in four patients (50%) at both 10 and 52 weeks (Fig. 1B).

Click to view

Table 1. Baseline Demographic Variables of the Eight Patients With Intestinal BD Refractory to Conventional Medications Who Were Given ADA

Click to view

Table 2. Clinical Course up to 52 Weeks

Click for large image

Figure 1. Evolution of the percentage of global GI symptom score 0 or ≤ 1 (A) and endoscopic assessment score 0 or ≤ 1 (B) at 10 and 52 weeks in the eight cases receiving ADA. Data are presented as mean ± SEM.

Mean C-reactive protein (CRP) level in eight patients receiving ADA was 0.98 ± 0.64 mg/dL at baseline. This decreased to 0.17 ± 0.08 mg/dL at 10 weeks and 0.16 ± 0.05 mg/dL at 52 weeks, showing no significant difference (Table 2). All patients taking PSL were able to taper off by 10 weeks after starting ADA. No adverse events were observed in any patients during the 52 weeks. ADA therapy was therefore considered safe and well tolerated.

We have reported herein the efficacy of ADA induction and maintenance in eight consecutive cases with intestinal BD.

Regarding anti-TNF-α antibodies for intestinal BD, a retrospective clinical cohort study investigating the efficacy of IFX in 43 patients with refractory intestinal BD showed that 12 patients (80%) responded to IFX, and that eight patients (53%) were in remission with no GI symptoms and normal CRP level at 10 weeks. In addition, response to IFX was maintained in seven of the 11 patients (64%) receiving maintenance therapy for 12 months. However, the cumulative recurrence rates at 12 and 24 months were 29% and 51%, respectively, and the cumulative surgery rates at 12 and 24 months were 13% and 37%, respectively [13]. The first prospective clinical trial investigating the efficacy of ADA in 20 patients with refractory intestinal BD showed that eight patients (40%) and 12 patients (60%) achieved MI in week 8 - 12 and week 52, respectively. In addition, three patients (15%) and four patients (20%) achieved complete remission in week 8 - 12 and week 52, respectively. These suggest that in clinical settings, anti-TNF-α antibodies such as IFX and ADA are efficacious therapies to induce and maintain clinical improvement and remission in patients with intestinal BD. Moreover, these effects are supported by the pathogenesis of BD, in which increased expression of TNF-α by γδT cells and monocytes in peripheral blood has been confirmed in patients with active BD [14, 15], and increased levels of TNF-α mRNA have been detected in ulcer lesions, which decrease after treatment [16].

In addition, of the five patients receiving PSL, PSL could be withdrawn at 10 weeks in all patients (100%) (Table 2). The clinical trial of ADA for the treatments of immune-mediated diseases such as Crohn’s disease and intestinal BD demonstrated that 29% of Crohn’s disease patients at 56 weeks [17] and 61.5% of intestinal BD patients at 52 weeks [10] taking corticosteroids at baseline who were treated with the ADA 40 mg every other week maintenance therapy could discontinue corticosteroids, respectively. These suggest that ADA treatment is useful to taper off corticosteroids.

However, patients with intestinal BD often fail to respond to anti-TNF-α antibodies [13]. In addition, even if dose-escalation of ADA to 80 mg every other week was tried and an increased trough level of serum ADA is maintained in patients with inadequate response or disease flare, some patients fail to achieve MI and clinical remission [10]. ADA monotherapy for refractory intestinal BD thus has limitations.

In conclusion, ADA is an effective, well-tolerated treatment of intestinal BD in patients who are refractory to conventional therapy.

Conflict of Interests

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Abbreviations

BD: Behcet’s disease; ADA: adalimumab; 5-ASA: 5-aminosalicylic acid; TNF: tumor necrosis factor; IFX: infliximab; MLZ: mesalazine; PSL: prednisolone; AZA: azathioprine; GI: gastrointestinal; MI: marked improvement; LOCF: last observation carried forward; CRP: C-reactive protein

1. Saadoun D, Wechsler B. Behcet's disease. Orphanet J Rare Dis. 2012;7:20.
   doi pubmed
2. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med. 1999;341(17):1284-1291.
   doi pubmed
3. Hisamatsu T, Ueno F, Matsumoto T, Kobayashi K, Koganei K, Kunisaki R, Hirai F, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease: indication of anti-TNFalpha monoclonal antibodies. J Gastroenterol. 2014;49(1):156-162.
   doi pubmed
4. Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol. 2012;46(5):e38-45.
   doi pubmed
5. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008;67(12):1656-1662.
   doi pubmed
6. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroenterology. 2001;120(4):995-999.
   doi pubmed
7. Comarmond C, Wechsler B, Cacoub P, Saadoun D. Approaches to immunosuppression in Behcet's disease. Immunotherapy. 2013;5(7):743-754.
   doi pubmed
8. Okada AA, Goto H, Ohno S, Mochizuki M. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol. 2012;130(5):592-598.
   doi pubmed
9. Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41(1):61-70.
   doi pubmed
10. Tanida S, Inoue N, Kobayashi K, Naganuma M, Hirai F, Iizuka B, Watanabe K, et al. Adalimumab for the treatment of Japanese patients with intestinal Behcet's disease. Clin Gastroenterol Hepatol. 2015;13(5):940-948 e943.
11. De Cassan C, De Vroey B, Dussault C, Hachulla E, Buche S, Colombel JF. Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's disease. J Crohns Colitis. 2011;5(4):364-368.
    doi pubmed
12. Japan. BsDRCo. Behcet's disease: guide to diagnosis of Behcet's disease. Jpn J Ophthalmol. 1974;18:291-294.
13. Kinoshita H, Kunisaki R, Yamamoto H, Matsuda R, Sasaki T, Kimura H, Tanaka K, et al. Efficacy of infliximab in patients with intestinal Behcet's disease refractory to conventional medication. Intern Med. 2013;52(17):1855-1862.
    doi pubmed
14. Yamashita N, Kaneoka H, Kaneko S, Takeno M, Oneda K, Koizumi H, Kogure M, et al. Role of gammadelta T lymphocytes in the development of Behcet's disease. Clin Exp Immunol. 1997;107(2):241-247.
    doi pubmed
15. Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T, Ueda A, et al. Cytokine production profile in patients with Behcet's disease treated with infliximab. Cytokine. 2003;24(5):210-218.
    doi pubmed
16. Kappen JH, Dik WA, Dingjan GM, van Daele PL, Hooijkaas H, van Hagen PM, van Laar JA. Cytokines in the colon of a patient with Behcet's disease. Arthritis Res Ther. 2009;11(4):412.
    doi pubmed
17. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132(1):52-65.
    doi pubmed

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Journal of Clinical Medicine Research is published by Elmer Press Inc.